|
FDA to streamline path for medical device review. |
 |
|
FDA: The U.S. Food and Drug Administration today unveiled a plan containing 25 actions it intends to implement during 2011 to improve the most common path to market for medical devices. Key actions include: ........................ * Streamlining the “de novo” review process for certain innovative, lower-risk medical devices,................... * Clarifying when clinical data should be submitted in a premarket submission, guidance that will increase the efficiency and transparency of the review process,..................... * Establishing a new Center Science Council of senior FDA experts to assure timely and consistent science-based decision making.
|